Does carvedilol therapy reduce QT dispersion in patients with heart failure?

Archives of Medical Science

Volumn 4, Issue 4, 2008, Pages 404-408

  Tatli, Ersan ^a   Aktoz, Meryem ^a   Gul, Cetin ^a   Buyuklu, Mutlu ^a   Kurum, Turhan ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

Carvedilol; Cytokines; Heart failure; QT dispersion

Indexed keywords

CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART SCINTISCANNING; HUMAN; MALE; MORBIDITY; MORTALITY; QT DISPERSION; REST; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 60249097877     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kuo CS, Munakata K, Reddy CP. Characteristics and possible mechanisms of ventricular arrhythmia dependent on the dispersion of action potential duration. Circulation 1983; 67: 1356-67.
2. Bonnar CE, Davie AP, Caruana L, et al. QT dispersion in patients with chronic heart failure: beta blockers are associated with a reduction in QT dispersion. Heart 1999; 81: 297-302.
3. Yee KM, Struthers AD. Can drug effects on mortality in heart failure be predicted by any surrogate marker? Eur Heart J 1997; 18: 1860-4.
4. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994; 343: 327-9.
5. Fu GS, Meissner A, Simon R. Repolarization dispersion and sudden cardiac death in patients with impaired left ventricular function. Eur Heart J 1997; 18: 281-9.
6. Francis GS. Development of arrhythmias in the patient with congestive heart failure: pathophysiology, prevalence and prognosis. Am J Cardiol 1986; 57: 3B-7B.
7. Metra M, Giubbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2001; 102: 546-51.
8. Reiber JH. Quantitative analysis of left ventricular function from equilibrium gated blood scintigrams: an overview of computer methods. Eur J Nucl Med 1985; 10: 97-110.
9. Bazzet HC. An analysis of time relation of electrocardiogram. Heart 1920; 28: 67-73.
10. Galinier M, Vialette JC, Fourcade J, et al. QT interval dispersion as a predictor of arrhythmic events in congestive heart failure. Importance of aetiology. Eur Heart J 1998; 19: 1054-62.
11. Louis A, Cleland JG, Crabbe S, et al. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001; 3: 381-7.
12. Jepson N, Farshid A, Friend C, Allan R, Walsh W. Carvedilol reduces QT interval dispersion in patients with chronic heart failure. J Am Coll Cardiol 1999; 33: 200A [Abstract].
13. Yildirir A, Sade E, Tokgozoglu L, Oto A. The effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure. Eur J Heart Fail 2001; 3: 717-21.
14. Akdeniz B, Guneri S, Savas IZ, et al. Effects of carvedilol therapy on arrhythmia markers in patients with congestive heart failure. Int Heart J 2006; 47: 565-73.
15. Pratt CM. Three decades of clinical trials with beta-blockers: the contribution of the CAPRICORN trial and the effect of carvedilol on serious arrhythmias. J Am Coll Cardiol 2005; 45: 531-2
16. Cice G, Tagliamonte E, Ferrara L, Iacono A. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study. Eur Heart J 2000; 21: 1259-64.
17. Ruffolo RR Jr, Boyle DA, Venuti RP, Lukas MA. Pre clinical and clinical pharmacology of carvedilol. J Hum Hypertens 1993; 7: S2-S15.
18. El-Sherif N, Turitto G. Electrophysiologic effects of carvedilol: is carvedilol an antiarrhythmic agent? Pacing Clin Electrophysiol 2005; 28: 985-90.
19. Kowalewski M, Urban M, Mroczko B, Szmitkowski M. Proinflammatory cytokines (IL-6, TNF-alpha) and cardiac troponin I (cTnI) in serum of young people with ventricular arrhythmias [Polish]. Pol Arch Med Wewn 2002; 108: 647-51
20. Mizuochi Y, Okajima K, Harada N, et al. Carvedilol, a nonselective beta-blocker, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. Transl Res 2007; 149: 223-30.
21. Tatli E, Kurum T. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytoklnes levels in patients with dilated cardiomyopathy. Can J Cardiol 2005; 21: 344-8.